Anders Lannergård
Consultant at Department of Medical Sciences; Infection medicine
- Telephone:
- +46 18 611 56 61
- E-mail:
- Anders.Lannergard@medsci.uu.se
- Visiting address:
- Akademiska sjukhuset
Infektion, ingång 34, 1 tr - Postal address:
- Akademiska sjukhuset
Infektion, ingång 34, 1 tr
751 85 Uppsala
Publications
Recent publications
-
Part of Harm Reduction Journal, 2023
- DOI for Prevalence, risk factors, treatment uptake and treatment outcome of hepatitis C virus in people who inject drugs at the needle and syringe program in Uppsala, Sweden
- Download full text (pdf) of Prevalence, risk factors, treatment uptake and treatment outcome of hepatitis C virus in people who inject drugs at the needle and syringe program in Uppsala, Sweden
-
Part of Scandinavian Journal of Gastroenterology, p. 1042-1050, 2019
- DOI for Effect of the baseline Y93H resistance-associated substitution in HCV genotype 3 for direct-acting antiviral treatment: real-life experience from a multicenter study in Sweden and Norway
- Download full text (pdf) of Effect of the baseline Y93H resistance-associated substitution in HCV genotype 3 for direct-acting antiviral treatment: real-life experience from a multicenter study in Sweden and Norway
-
Part of Upsala Journal of Medical Sciences, p. 50-56, 2018
- DOI for The effect of the first-generation HCV-protease inhibitors boceprevir and telaprevir and the relation to baseline NS3 resistance mutations in genotype 1: experience from a small Swedish cohort
- Download full text (pdf) of The effect of the first-generation HCV-protease inhibitors boceprevir and telaprevir and the relation to baseline NS3 resistance mutations in genotype 1: experience from a small Swedish cohort
-
Part of BMC Psychiatry, 2018
- DOI for Direct-acting antiviral treatment in real world patients with hepatitis C not associated with psychiatric side effects: a prospective observational study
- Download full text (pdf) of Direct-acting antiviral treatment in real world patients with hepatitis C not associated with psychiatric side effects: a prospective observational study
-
Part of Scandinavian Journal of Gastroenterology, p. 1347-1353, 2018
- DOI for Personalized treatment of hepatitis C genotype 1a in Norway and Sweden 2014-2016: a study of treatment outcome in patients with or without resistance-based DAA-therapy.
- Download full text (pdf) of Personalized treatment of hepatitis C genotype 1a in Norway and Sweden 2014-2016: a study of treatment outcome in patients with or without resistance-based DAA-therapy.
All publications
Articles in journal
-
Part of Harm Reduction Journal, 2023
- DOI for Prevalence, risk factors, treatment uptake and treatment outcome of hepatitis C virus in people who inject drugs at the needle and syringe program in Uppsala, Sweden
- Download full text (pdf) of Prevalence, risk factors, treatment uptake and treatment outcome of hepatitis C virus in people who inject drugs at the needle and syringe program in Uppsala, Sweden
-
Part of Scandinavian Journal of Gastroenterology, p. 1042-1050, 2019
- DOI for Effect of the baseline Y93H resistance-associated substitution in HCV genotype 3 for direct-acting antiviral treatment: real-life experience from a multicenter study in Sweden and Norway
- Download full text (pdf) of Effect of the baseline Y93H resistance-associated substitution in HCV genotype 3 for direct-acting antiviral treatment: real-life experience from a multicenter study in Sweden and Norway
-
Part of Upsala Journal of Medical Sciences, p. 50-56, 2018
- DOI for The effect of the first-generation HCV-protease inhibitors boceprevir and telaprevir and the relation to baseline NS3 resistance mutations in genotype 1: experience from a small Swedish cohort
- Download full text (pdf) of The effect of the first-generation HCV-protease inhibitors boceprevir and telaprevir and the relation to baseline NS3 resistance mutations in genotype 1: experience from a small Swedish cohort
-
Part of BMC Psychiatry, 2018
- DOI for Direct-acting antiviral treatment in real world patients with hepatitis C not associated with psychiatric side effects: a prospective observational study
- Download full text (pdf) of Direct-acting antiviral treatment in real world patients with hepatitis C not associated with psychiatric side effects: a prospective observational study
-
Part of Scandinavian Journal of Gastroenterology, p. 1347-1353, 2018
- DOI for Personalized treatment of hepatitis C genotype 1a in Norway and Sweden 2014-2016: a study of treatment outcome in patients with or without resistance-based DAA-therapy.
- Download full text (pdf) of Personalized treatment of hepatitis C genotype 1a in Norway and Sweden 2014-2016: a study of treatment outcome in patients with or without resistance-based DAA-therapy.
-
Part of Diagnostics (Basel), 2018
- DOI for Enhanced Systemic Response of Matrix Metalloproteinases and Their Regulators in Campylobacter and Salmonella Patients
- Download full text (pdf) of Enhanced Systemic Response of Matrix Metalloproteinases and Their Regulators in Campylobacter and Salmonella Patients
-
Part of Biological Psychiatry, 2017
-
Part of Infection Ecology & Epidemiology, 2015
-
Part of INFECTIOUS DISEASES, p. 555-562, 2015
-
Vanligt med antibiotikaresistens hos barn med urinvägsavledning
Part of Läkartidningen, p. 2376-2379, 2011
-
Diagnostik vid virala hepatiter i ett kliniskt perspektiv
Part of Klinisk Biokemi i Norden, p. 10-14, 2010
-
Part of Scandinavian Journal of Infectious Diseases, p. 663-671, 2009
-
Part of Acta Paediatrica, p. 1061-1065, 2008
-
A population pharmacokinetic model for cefuroxime using cystatin C as a marker of renal function
Part of British Journal of Clinical Pharmacology, p. 297-303, 2006
-
Part of Acta Paediatrica, p. 1198-1202, 2005